Efalizumab; Natalizumab/Immunosuppressives; Immunomodulators Interactions
This information is generalized and not intended as specific medical advice. Consult your healthcare professional before taking or discontinuing any drug or commencing any course of treatment.
Severe. These medicines may interact and cause very harmful effects and are usually not taken together. Contact your healthcare professional (e.g. doctor or pharmacist) for more information.
How the interaction occurs:
All of these medicines can decrease your body's ability to fight infections.
What might happen:
You may have a higher risk of an infection while taking both medicines.
What you should do about this interaction:
Let your healthcare professionals (e.g. doctor or pharmacist) know right away that you are taking these medicines together or if you have previously taken any immunosuppressives. Let your doctor know if you have any signs of an infection.Your healthcare professionals may already be aware of this interaction and may be monitoring you for it. Do not start, stop, or change the dosage of any medicine before checking with them first.
- 1.Tysabri (natalizumab) UK summary of product characteristics. Biogen Idec Ltd January, 2009.
- 2.Tysabri (natalizumab) Canadian prescribing information. Biogen Idec Canada, Inc. January 9, 2009.
- 3.Tysabri (natalizumab) US prescribing information. Biogen Idec, Inc. May, 2016.
- 4.Raptiva (efalizumab) US prescribing information. Genentech, Inc. March 13, 2009.
- 5.USFood and Drug Administration. FDA Drug Safety Communication: New risk factor for Progressive Multifocal Leukoencephalopathy (PML) associated with Tysabri (natalizumab). available at: http://www.fda.gov/Drugs/DrugSafety/ucm288186.htm January 20, 2012.
- 6.Medical Information. Personal communication. Biogen Idec, Inc. December 1, 2004.
- 7.Cimzia (certolizumab pegol) US prescribing information. UCB, Inc. February, 2019.
- 8.Kleinschmidt-DeMasters BK, Tyler KL. Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. N Engl J Med 2005 Jul 28;353(4):369-74.
- 9.Langer-Gould A, Atlas SW, Green AJ, Bollen AW, Pelletier D. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N Engl J Med 2005 Jul 28;353(4):375-81.
CONDITIONS OF USE: The information in this database is intended to supplement, not substitute for, the expertise and judgment of healthcare professionals. The information is not intended to cover all possible uses, directions, precautions, drug interactions or adverse effects, nor should it be construed to indicate that use of a particular drug is safe, appropriate or effective for you or anyone else. A healthcare professional should be consulted before taking any drug, changing any diet or commencing or discontinuing any course of treatment.